Lively Biotech has obtained optimistic suggestions from regulators on a protocol modification to its ongoing proof-of-concept scientific trial evaluating tasquinimod in sufferers with myelofibrosis, a...
The U.S. Meals and Drug Administration (FDA) has accepted PD-L1 IHC 22C3 pharmDx, Code SK006, as a companion diagnostic to assist establish sufferers with epithelial...
Ribociclib Boosts PFS in HR+/HER2– Superior Breast Most cancersFrontline remedy with ribociclib (Kisqali) plus endocrine remedy considerably improved progression-free survival (PFS) with superior...
